GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human PI3K-gamma in complex with CH5039699

Analyse Crystal structure of human PI3K-gamma in complex with CH5039699 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3APF
Type
protein
Length
840 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
2.82
Source
Homo sapiens
Molecule
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
EC
2.7.1.153
UniProt
P48736
Ligands
BMW, SO4
Pockets
13 · best druggability 0.83

Structure

x-ray diffraction · resolution 2.82 · 1 distinct chain · 44% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (EC 2.7.1.153)protein84044% helix, 17% strandP48736

Ligands and binding sites

  • BMW · 3-[7-(1H-benzimidazol-5-yl)-2-(morpholin-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]phenol · ligand · chains A
  • SO4 · Sulfate ion · ion · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

13 pockets found on a 1 Å grid, 5 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110720.830.8486empty
2610.700.9720empty
34070.660.7943empty
43520.650.7937SO4, BMW
52300.560.7932empty

Compared structures

  • 3APF · Crystal structure of human PI3K-gamma in complex with CH5039699 · the same entry in another collection · chain A against A, TM-score 1.00
  • P48736 · AlphaFold monomer V2.0 prediction for phosphatidylinositol 4,5-bisphosphate 3-kinase… · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.